<h1>Sensipar</h1><p> Sensipar lowers serum calcium; therefore, it is important that patients have a serum calcium greater than or equal to 8.4 mg/dL when initiating therapy. Adynamic bone disease may develop if intact parathyroid hormone (iPTH) levels are suppressed below 100 pg/mL. Patients with moderate to severe hepatic impairment should be monitored throughout treatment with Sensipar, as cinacalcet exposure assessed by area under the curve (AUC) was higher than patients with normal hepatic function.
Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.
The most commonly reported side effects were nausea, vomiting, and diarrhea.</p>
Serum calcium and serum phosphorus should be measured within 1 week and PTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and PTH every 1 to 3 months.
The most commonly reported side effects were nausea, vomiting, and diarrhea.</p>
